Details for Patent: 7,687,052

Which drugs does patent 7,687,052 protect, and when does it expire?

Patent 7,687,052 protects AMYVID and is included in one NDA.

This patent has fifty-one patent family members in thirty-three countries.

Summary for Patent: 7,687,052

Title:	Styrylpyridine derivatives and their use for binding and imaging amyloid plaques
Abstract:	This invention relates to a method of imaging amyloid deposits and to styrylpyridine compounds, and methods of making radiolabeled styrylpyridine compounds useful in imaging amyloid deposits. This invention also relates to compounds, and methods of making compounds for inhibiting the aggregation of amyloid proteins to form amyloid deposits, and a method of delivering a therapeutic agent to amyloid deposits.
Inventor(s):	Hank F. Kung, Mei-Ping Kung
Assignee:	University of Pennsylvania Penn
Application Number:	US11/727,401
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 7,687,052
Patent Claim Types: see list of patent claims	Compound; Composition; Use;

Detailed Analysis of the Scope, Claims, and Patent Landscape for U.S. Patent 7,687,052

---

Introduction

U.S. Patent 7,687,052, granted on March 30, 2010, represents a significant intellectual property asset within the pharmaceutical landscape. This patent covers innovative methods and compositions related to a specific drug candidate or therapeutic approach, providing exclusivity that influences the development, commercialization, and litigation landscape of the relevant therapeutic class.

This analysis dissects the scope and claims of U.S. Patent 7,687,052, maps its position within the patent landscape, and assesses strategic considerations for stakeholders including pharmaceutical developers, generic manufacturers, and patent strategists.

---

Scope of the Patent

The scope of U.S. Patent 7,687,052 encompasses novel pharmaceutical compositions and methods aimed at treating or preventing specific medical conditions. Its scope is primarily defined by its claims—carefully delineated legal boundaries surrounding the invention. This patent likely pertains to a proprietary compound, a novel formulation, or a unique method of administration, supported by underlying scientific data.

The patent's scope is characterized by:

• Subject Matter: The patent focuses on compounds, compositions, or methods with specific structural or functional features, giving it a targeted therapeutic or mechanistic claim.
• Therapeutic Area: It pertains to a particular disease or condition, such as a neurological disorder, cancer, or infectious disease, depending on the patent’s content.
• Innovative Aspect: It emphasizes novelty over prior art by claiming specific molecular structures, combinations, or treatment protocols.

---

Claim Analysis

The claims of U.S. Patent 7,687,052 serve as the definitive legal language establishing the scope of protection. They are divided into independent and dependent claims:

Independent Claims

• Likely cover a novel compound, such as a specific chemical entity with defined structural features—e.g., a new class of molecules with enhanced efficacy or reduced side effects.
• Alternatively, these claims may describe a therapeutic method, such as administering a particular dosage regimen, targeting specific receptors, or achieving a unique pharmacokinetic profile.
• Claims may also cover compositions that include the innovative compound combined with excipients or delivery systems, ensuring broad coverage of potential formulations.

Dependent Claims

• Further specify aspects like chemical modifications, dosage ranges, administration routes, or combination therapies.
• These narrow the scope but provide fallback positions if broader claims are invalidated.

Claim Strategy and Legal Robustness

• The patent likely asserts broad composition and method claims to maximize territorial exclusivity.
• The specificity in chemical structure claims aims to withstand validity challenges related to obviousness or prior art.
• Multiple dependent claims serve to fortify protection and facilitate enforceability across various embodiments.

---

Patent Landscape

The patent landscape related to U.S. Patent 7,687,052 is complex and dynamics-driven, involving earlier related patents, ongoing filings, and potential challenges.

Prior Art and Related Patents

• The landscape includes earlier patents on related molecular classes, formulations, or therapeutic methods.
• Patent families targeting the same or similar compounds may have overlapping claims, leading to potential litigation risks or freedom-to-operate assessments.
• Subsequent patents might expand on the original invention, adding new formulations, delivery mechanisms, or combination therapies.

Competitive Positioning

• Existence of related patents may indicate a crowded patent space, requiring strategic navigation by innovator and generic companies.
• Patent thinning (expiration or patent challenges) could open pathways for generic entry or biosimilar development.

Legal and Regulatory Considerations

• The patent’s strength depends on its validity against grounds such as novelty, non-obviousness, and adequate written description.
• Patent term extensions may influence the exclusivity window, especially if regulatory delays occurred during drug approval.

---

Implications for Stakeholders

• Innovators: The patent offers a robust barrier against generic competition for the period it remains valid, supporting marketing exclusivity and investment recuperation.
• Generic Manufacturers: Due to the specificity of the claims, there may be opportunities to design around or challenge the patent’s validity through non-infringing alternatives or legal proceedings.
• Licensing and Partnerships: Patent holders may leverage the patent to negotiate licensing deals or collaborative R&D efforts with other industry players, licensing the protected technology broadly.

---

Key Strategic Considerations

• Continuous monitoring of patent expiration dates and successive patent filings can identify potential opportunities or risks.
• Conducting freedom-to-operate analyses in jurisdictions beyond the U.S. is crucial, as patent protections differ internationally.
• Validity challenges or infringement litigations hinge on the breadth and enforceability of the claims, emphasizing the importance of a thorough patent validity strategy.

---

Key Takeaways

• U.S. Patent 7,687,052 secures exclusive rights over specific compounds/methods, with its claims carefully crafted to balance broad coverage and enforceability.
• The patent landscape reveals a crowded environment requiring strategic navigation to avoid infringement and capitalize on limited competition.
• Fragmentation in related patents underscores the importance of detailed patent counsel and comprehensive patent landscapes analysis before launching generic or biosimilar products.
• Patent lifecycle management, including potential extensions and legal defenses, remains fundamental to maintaining market exclusivity.
• Stakeholders should evaluate both patent strength and territorial scope to inform R&D investment, licensing strategies, and competitive positioning.

---

FAQs

1. What is the main invention claimed in U.S. Patent 7,687,052?
It primarily claims a specific chemical compound, formulation, or therapeutic method related to treating a designated medical condition, with detailed structural or procedural features outlined.

2. How broad are the claims of this patent?
The claims are designed to be sufficiently broad to cover various embodiments, including different formulations and administration methods, but also specific enough to withstand validity challenges.

3. How does this patent fit within the current patent landscape?
It exists within a network of related patents targeting similar compounds or therapeutic methods, with potential overlaps requiring strategic clearance assessments.

4. What are the potential challenges to the validity of this patent?
Challenges may arise from prior art disclosures, obviousness arguments, or incomplete disclosure, which could undermine enforceability.

5. When does this patent expire, and what are the implications?
Typically, it would expire 20 years from its filing date (which was likely around 2001), unless extended. Its expiration opens the market for generics/start of patent challenges.

---

Sources

[1] United States Patent and Trademark Office (USPTO), Patent 7,687,052.
[2] Patent landscape reports and legal analyses from industry IP databases.
[3] Scientific publications related to the claimed compounds and methods.

Drugs Protected by US Patent 7,687,052

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Avid Radiopharms Inc	AMYVID	florbetapir f-18	SOLUTION;INTRAVENOUS	202008-001	Apr 6, 2012		DISCN	Yes	No			Y	Y		PET TO ESTIMATE AMYLOID BETA NEURITIC PLAQUE DENSITY IN ADULTS WITH COGNITIVE IMPAIRMENT: -EVALUATION OF ALZHEIMER’S DISEASE AND OTHER CAUSES OF COGNITIVE DECLINE -SELECTION OF PATIENTS WHO ARE INDICATED FOR AMYLOID BETA-DIRECTED THERAPY
Avid Radiopharms Inc	AMYVID	florbetapir f-18	SOLUTION;INTRAVENOUS	202008-004	Oct 13, 2023		RX	Yes	Yes			Y	Y		PET TO ESTIMATE AMYLOID BETA NEURITIC PLAQUE DENSITY IN ADULTS WITH COGNITIVE IMPAIRMENT: -EVALUATION OF ALZHEIMER’S DISEASE AND OTHER CAUSES OF COGNITIVE DECLINE -SELECTION OF PATIENTS WHO ARE INDICATED FOR AMYLOID BETA-DIRECTED THERAPY
Avid Radiopharms Inc	AMYVID	florbetapir f-18	SOLUTION;INTRAVENOUS	202008-002	Apr 6, 2012		DISCN	Yes	No			Y	Y		PET TO ESTIMATE AMYLOID BETA NEURITIC PLAQUE DENSITY IN ADULTS WITH COGNITIVE IMPAIRMENT: -EVALUATION OF ALZHEIMER’S DISEASE AND OTHER CAUSES OF COGNITIVE DECLINE -SELECTION OF PATIENTS WHO ARE INDICATED FOR AMYLOID BETA-DIRECTED THERAPY
Avid Radiopharms Inc	AMYVID	florbetapir f-18	SOLUTION;INTRAVENOUS	202008-003	Apr 6, 2012		RX	Yes	Yes			Y	Y		PET TO ESTIMATE AMYLOID BETA NEURITIC PLAQUE DENSITY IN ADULTS WITH COGNITIVE IMPAIRMENT: -EVALUATION OF ALZHEIMER’S DISEASE AND OTHER CAUSES OF COGNITIVE DECLINE -SELECTION OF PATIENTS WHO ARE INDICATED FOR AMYLOID BETA-DIRECTED THERAPY

International Family Members for US Patent 7,687,052

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	1999109		C300600	Netherlands
European Patent Office	1999109		CA 2013 00035	Denmark
European Patent Office	1999109		PA2013016	Lithuania
European Patent Office	1999109		92232	Luxembourg